# CryoTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cryotherapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Belgium
- Website: www.cryotherapeutics.com
- Total disclosed funding: $31M
- Latest round: Series B (Mar 28, 2024)
- Investors on record: 9

## About

Based in Belgium, CryoTherapeutics SA specializes in medical technology for preventing and treating heart attacks through innovative cryotherapy solutions. Their primary focus is on providing advanced catheter systems designed for interventional cardiology.Founded in 2009 in Belgium, CryoTherapeutics SA is focused on developing cryotherapy solutions that address heart disease. The company has engaged in a total of 6 deals, with their latest investment round being a Series B funding of EUR 10.00 mn completed on April 2, 2024, involving investors such as Buenavista Ventures and KfW Banking Group. The current CEO is John Yianni.CryoTherapeutics specializes in innovative medical technology aimed at preventing and treating heart attacks through the application of cryotherapy. Their primary offering is a patented catheter system that delivers cryoenergy between -10°C and -20°C directly to diseased sections of coronary arteries. This method promotes arterial repair without the need for permanent stent placement, addressing a significant gap in cardiology interventions, particularly in stabilizing atherosclerotic plaque, a precursor to heart attacks. The technology is designed for use by interventional cardiologists, targeting individuals at risk of cardiovascular disease, and is positioned for markets across Europe and the United States.CryoTherapeutics generates revenue primarily through direct sales of its proprietary catheter technology to hospitals and healthcare providers specializing in cardiology. Transactions typically involve healthcare institutions purchasing the catheter systems for use in interventional procedures, reflecting a business-to-business model. Partnerships with medical centers and cardiology clinics facilitate the integration of their cryotherapy solutions into existing treatment protocols, enhancing the company's market presence in treating cardiovascular diseases. In 2022, the company's EBITDA was EUR -742,545.70.In April 2024, CryoTherapeutics SA raised EUR 10.00 mn in Series B funding to support the development of its cryotherapy technology. The company plans to leverage this funding to design and launch new product offerings while expanding into additional markets, particularly in Europe and the United States, to enhance its reach in addressing healthcare needs related to heart disease.

## Funding rounds

- Series B, Mar 28, 2024, $7.6M — KfW Banking Group, NRW Bank, Peppermint VenturePartners, Noshaq, Buenavista Ventures, Yellowstone Holding
- Series B, Mar 8, 2019, $9.2M — Creathor Ventures, Peppermint VenturePartners, Getz Bros., Noshaq
- Series B, Jul 7, 2016, $5.8M — KfW Banking Group, Creathor Ventures, NRW Bank, Peppermint VenturePartners, High-Tech Gruenderfonds, Getz Bros.
- Series A, May 6, 2014, $4.8M — KfW Banking Group, NRW Bank, Peppermint VenturePartners, High-Tech Gruenderfonds, Getz Bros.
- Series A, Mar 21, 2013, $3.9M — Peppermint VenturePartners
- Series A, Jun 1, 2012 — NRW Bank, High-Tech Gruenderfonds, Getz Bros.

## Investors

- NRW Bank — Series A, Series B
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A, Series B
- Getz Bros. — Series A, Series B
- Peppermint VenturePartners (https://capitalatlas.ai/funds/peppermint-venturepartners) — Series A, Series B
- KfW Banking Group — Series A, Series B
- Creathor Ventures (https://capitalatlas.ai/funds/creathor-ventures) — Series B
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series B
- Buenavista Ventures — Series B
- Yellowstone Holding (https://capitalatlas.ai/funds/yellowstone-holding) — Series B